N-butyloxycarbonyl-3-[4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl-methyl)-phenyl]-5-isobutylthiophene-2-sulfonamide | 695226-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: N-butyloxycarbonyl-3-[4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl-methyl)-phenyl]-5-isobutylthiophene-2-sulfonamide
• 英文别名: N-butyloxycarbonyl-3-[4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-ylmethyl)phenyl]-5-iso-butylthiophene-2-sulfonamide；butyl N-[5-(2-methylpropyl)-3-[4-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]phenyl]thiophen-2-yl]sulfonylcarbamate
• CAS: 695226-59-6
• 化学式: C₂₆H₃₅N₃O₆S₂
• 分子量: 549.712
• InChiKey: UKRFYSFACFQMFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  150
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-[4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-ylmethyl)phenyl]-5-iso-butylthiophene-2-sulfonamide 、 氯甲酸丁酯 在 吡啶 、 2-(吡咯烷-1-基)吡啶 作用下， 以71%的产率得到N-butyloxycarbonyl-3-[4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl-methyl)-phenyl]-5-isobutylthiophene-2-sulfonamide
  参考文献：
  名称：

  [EN] NEW TRICYCLIC ANGIOTENSIN II AGONISTS
  [FR] NOUVEAUX AGONISTES TRICYCLIQUES DE L'ANGIOTENSINE II

  摘要：

  提供了具有式（I）的化合物，其中虚线，X1，X2，X3，A，Y1，Y2，Y3，Y4，Z1，Z2，R2和R3的含义如描述中所给，并且其药学上可接受的盐，这些化合物可用作AT2受体的选择性激动剂，因此，特别适用于治疗包括消化不良、肠易激综合征和多器官功能衰竭在内的胃肠道疾病和心血管疾病。

  公开号：

  WO2004046137A1

文献信息

• Selective angiotensin II AT2 receptor agonists with reduced CYP 450 inhibition
  作者：A.K. Mahalingam、Yiqian Wan、A.M.S. Murugaiah、Charlotta Wallinder、Xiongyu Wu、Bianca Plouffe、Milad Botros、Fred Nyberg、Anders Hallberg、Nicole Gallo-Payet

  DOI：10.1016/j.bmc.2010.03.064

  日期：2010.6.15

  Structural alterations to the benzylic position of the first drug-like selective angiotensin II AT(2) receptor agonist (1) have been performed, with the emphasis to reduce the CYP 450 inhibitory property of the initial structure. The imidazole moiety, responsible for the CYP 450 inhibitory effect in 1, was replaced with various heterocycles. In addition, the modes of attachment of the heterocycles, that is, carbon versus nitrogen attachment, and introduction of carbonyl functionalities to the benzylic position have been evaluated. In all the three series, AT(2) receptor ligands with affinity in the lower nanomolar range were identified. None of the analogues, regardless of the substituents, exhibited any affinity for the AT(1) receptor. Compounds with substantially reduced inhibition of the CYP 450 enzymes were obtained. Among them the compound 60 was found to induce neurite elongation in NG 108-15 cells and served as potent AT(2) selective agonist. (C) 2010 Elsevier Ltd. All rights reserved.
• [EN] NEW TRICYCLIC ANGIOTENSIN II AGONISTS<br/>[FR] NOUVEAUX AGONISTES TRICYCLIQUES DE L'ANGIOTENSINE II
  申请人：VICORE PHARMA AB

  公开号：WO2004046137A1

  公开（公告）日：2004-06-03

  There is provided compounds of formula (I), wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders

  提供了具有式（I）的化合物，其中虚线，X1，X2，X3，A，Y1，Y2，Y3，Y4，Z1，Z2，R2和R3的含义如描述中所给，并且其药学上可接受的盐，这些化合物可用作AT2受体的选择性激动剂，因此，特别适用于治疗包括消化不良、肠易激综合征和多器官功能衰竭在内的胃肠道疾病和心血管疾病。